AZIYO BIOLOGICS(US:AZYO)2025-08-14 20:11Revenue and Sales Performance - EluPro revenue increased by 49% sequentially in Q2 2025, contributing approximately two-thirds of total BioEnvelope sales, which reached $3.5 million, a 33% year-over-year increase[5] - The customer base for EluPro has grown more than 15 times since its launch, with over 160 VAC-approved hospitals now using the product[5] - Average sales per EluPro customer were 130% higher than for CanGaroo customers, indicating stronger procedure penetration[5] - The company expects BioEnvelope sales to approach a $20 million annualized run rate by year-end 2025[4] - Overall net sales for Q2 2025 were $6.3 million, consistent with Q2 2024, while net loss decreased to $9.6 million from $28.2 million[8] - Net sales for Q2 2025 were $6,263 million, a slight decrease of 0.4% compared to $6,291 million in Q2 2024[15] - Gross profit for Q2 2025 increased to $3,058 million, up 9.2% from $2,799 million in Q2 2024[15] - Adjusted gross profit (Non-GAAP) for Q2 2025 was $3,907 million, representing a 7.1% increase from $3,648 million in Q2 2024[16] Operating Expenses and Financial Metrics - Total operating expenses increased to $12.9 million in Q2 2025, compared to $11.3 million in the same period last year[8] - Total operating expenses for Q2 2025 were $12,933 million, an increase of 14.3% compared to $11,309 million in Q2 2024[15] - Adjusted EBITDA (Non-GAAP) for Q2 2025 was $(3,829) million, worsening from $(2,648) million in Q2 2024[18] - Net loss for Q2 2025 was $9,610 million, a significant improvement from a net loss of $28,180 million in Q2 2024[18] - Net loss per share (basic) for Q2 2025 was $(0.23), compared to $(1.13) in Q2 2024[15] - Cash balance as of June 30, 2025, was $8.5 million, down from $13.2 million at the end of 2024[13] Litigation and Legal Matters - The company has settled 97 of 110 FiberCel litigation cases, significantly reducing expected litigation expenses going forward[5] - Litigation costs for Q2 2025 were $4,004 million, significantly higher than $2,289 million in Q2 2024[18] Product Development and Market Strategy - Elutia is advancing its NXT-41 platform for breast reconstruction, targeting FDA clearance of the base matrix in 2H26 and the drug-eluting version in 1H27, addressing a $1.5 billion market[4] - Adjusted gross margin improved to 62.4% in Q2 2025, up from 58.0% in Q2 2024[8] - Gross margin for Q2 2025 improved to 48.8%, up from 44.5% in Q2 2024[16] - Weighted average common shares outstanding (diluted) increased to 46,308,642 in Q2 2025 from 24,900,167 in Q2 2024[15]